Menarini-Silicon Biosystems and Swift Biosciences Announce Collaboration to Offer Customized NGS Technologies for Tumor Cell Analysis
Products Optimized for Targeted Resequencing and Exome Sequencing of FFPE Cells
BOLOGNA, Italy – Menarini-Silicon Biosystems Inc., a developer and manufacturer of technologies and products that help uncover the biological complexities of disease at the single-cell level, and Swift Biosciences, Inc., a developer of innovative technologies for sample preparation for next-generation sequencing (NGS), today announced their collaboration to offer customized NGS products for oncology research and diagnostics. Marketed by Menarini-Silicon Biosystems, the first two products developed for tumor cells from formalin-fixed, paraffin-embedded (FFPE) tissue samples allow users to obtain high-quality, NGS results from 100 to 300 tumor and stromal cells in an optimized workflow downstream of Menarini-Silicon Biosystems’ DEPArray™ cell sorting platform.
“We are excited to continue our technology collaboration with Swift Biosciences to offer our customers reliable solutions for the genetic analysis of cells d

